Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDZBIQ)

• Drug Name: PMI-001 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Lupus	4A40	Discontinued in Phase 3	[1]

• Cross-matching ID:
  PubChem CID: 135497218
  TTD Drug ID: DMDZBIQ

Molecule-Related Drug Atlas

Drug(s) Targeting Interleukin-2 (IL2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aldesleukin	DM4YMIS	Acute myelogenous leukaemia	2A41	Approved	[3]
Daclizumab	DM6OZQV	Aplastic anemia	3A70	Approved	[4]
AIR-insulin	DM8SYTE	Diabetic complication	5A2Y	Phase 3	[5]
TG-4010	DMWE3GB	Bipolar disorder	6A60	Phase 2/3	[6]
BNZ-1	DM8JQZC	Cutaneous T-cell lymphoma	2B01	Phase 2	[7]
IL-2/CD40L-expressing leukemia vaccine	DMIHQ5G	Chronic lymphocytic leukaemia	2A82.0	Phase 2	[8]
Carboxyamidotriazole orotate	DMN5JCX	Glioblastoma multiforme	2A00.0	Phase 2	[9]
Leuvectin	DM5LQEI	Melanoma	2C30	Phase 2	[10]
Human interleukin-2	DM0NJWG	Renal cell carcinoma	2C90	Phase 2	[11]
L19-IL-2 fusion protein	DMI2XP1	Lymphoma	2A80-2A86	Phase 2	[12]

Drug(s) Targeting Prostaglandin G/H synthase 2 (COX-2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[13]
Naproxen	DMZ5RGV	Bursitis		Approved	[14]
Etodolac	DM6WJO9	Osteoarthritis	FA00-FA05	Approved	[15]
Indomethacin	DMSC4A7	Bursitis		Approved	[3]
Celecoxib	DM6LOQU	Dysmenorrhea	GA34.3	Approved	[16]
Nabumetone	DMAT2XH	Osteoarthritis	FA00-FA05	Approved	[17]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[18]
Flurbiprofen	DMGN4BY	Osteoarthritis	FA00-FA05	Approved	[19]
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Hypertriglyceridemia	5C80.1	Approved	[20]
Aminosalicylic Acid	DMENSL5	Crohn disease	DD70	Approved	[3]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin-2 (IL2)	TTF89GD	IL2_HUMAN	Inhibitor	[2]
Prostaglandin G/H synthase 2 (COX-2)	TTVKILB	PGH2_HUMAN	Inhibitor	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019789)
• [2] Development of a botanical anti-arthritis drug, PMI-001. SBIR.STTR America's Seed Fund.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [4] 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
• [5] The AIR inhaled insulin system: system components and pharmacokinetic/glucodynamic data. Diabetes Technol Ther. 2007 Jun;9 Suppl 1:S41-7.
• [6] A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J Thorac Oncol. 2008 Jul;3(7):735-44.
• [7] Clinical pipeline report, company report or official report of Bioniz Therapeutics.
• [8] Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and a... Blood. 2006 Feb 15;107(4):1332-41.
• [9] J Clin Oncol 32:5s, 2014 (suppl; abstr 2071).
• [10] Intratumoral interleukin 2 for renal-cell carcinoma by direct gene transfer of a plasmid DNA/DMRIE/DOPE lipid complex. World J Urol. 2000 Apr;18(2):152-6.
• [11] Clinical pipeline report, company report or official report of Immunservice.
• [12] National Cancer Institute Drug Dictionary (drug id 665656).
• [13] Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol. 2009 Sep;28(2):239-44.
• [14] Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
• [15] Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. Intern Med. 2007;46(13):1055-8.
• [16] Pfizer. Product Development Pipeline. March 31 2009.
• [17] Renal effects of nabumetone, a COX-2 antagonist: impairment of function in isolated perfused rat kidneys contrasts with preserved renal function in vivo. Exp Nephrol. 2001;9(6):387-96.
• [18] Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
• [19] Flurbiprofen, a cyclooxygenase inhibitor, protects mice from hepatic ischemia/reperfusion injury by inhibiting GSK-3 signaling and mitochondrial permeability transition.Mol Med.2012 Sep 25;18:1128-35.
• [20] Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.